Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VTYX

Ventyx Biosciences Inc

Nov 06 • 04:00PM ET

9.26

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA VRTX BIIB INCY GILD AMGN NBIX BMRN EXEL

| Held by: VTI SCHA VXF IWC AVSC VHT DFAS SCHB PRFZ QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.68	Insider Own	10.79%	Shs Outstand	71.23M	Perf Week	9.98%
Market Cap	660.32M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	0.00%	Shs Float	63.62M	Perf Month	141.78%
Enterprise Value	461.65M	PEG	-	EPS next Q	-0.40	Inst Own	63.18%	Short Float	2.20%	Perf Quarter	229.54%
Income	-119.03M	P/S	-	EPS this Y	21.95%	Inst Trans	-8.61%	Short Ratio	0.37	Perf Half Y	691.45%
Sales	0.00M	P/B	3.15	EPS next Y	-8.45%	ROA	-44.15%	Short Interest	1.40M	Perf YTD	322.83%
Book/sh	2.94	P/C	3.16	EPS next 5Y	5.54%	ROE	-48.56%	52W High	9.50 -2.53%	Perf Year	330.70%
Cash/sh	2.93	P/FCF	-	EPS past 3/5Y	-5.26% -87.13%	ROIC	-54.46%	52W Low	0.78 1082.63%	Perf 3Y	-72.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.24% 11.93%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	39.76%	Oper. Margin	-	ATR (14)	0.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	81.13	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	19.12	EPS Q/Q	16.30%	SMA20	55.29%	Beta	1.22	Target Price	13.75
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	126.93%	Rel Volume	0.00	Prev Close	9.26
Employees	82	LT Debt/Eq	0.04	Earnings	Nov 06 AMC	SMA200	277.81%	Avg Volume	3.76M	Price	9.26
IPO	Oct 21, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	28.70% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-25	Upgrade	H.C. Wainwright	Neutral → Buy	$18
Mar-12-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$7 → $16
Mar-12-24	Upgrade	Oppenheimer	Perform → Outperform	$12
Nov-07-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$77 → $8
Nov-07-23	Downgrade	Stifel	Buy → Hold	$6
Nov-07-23	Downgrade	Oppenheimer	Outperform → Perform
Nov-07-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$46 → $6
Nov-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-14-23	Resumed	Credit Suisse	Outperform	$63
Mar-21-23	Initiated	Wells Fargo	Overweight	$77
Dec-19-22	Initiated	Goldman	Buy	$50
Nov-17-22	Initiated	Morgan Stanley	Overweight	$45
Sep-07-22	Initiated	Stifel	Buy	$45
Sep-01-22	Initiated	H.C. Wainwright	Buy	$36
May-09-22	Initiated	Credit Suisse	Outperform	$53
Mar-31-22	Initiated	Canaccord Genuity	Buy	$30
Feb-01-22	Initiated	Oppenheimer	Outperform	$30
Nov-15-21	Initiated	Piper Sandler	Overweight	$50
Nov-15-21	Initiated	Jefferies	Buy	$30

Show Previous Ratings

Nov-06-25 04:02PM	Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Oct-26-25 06:43AM	Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk (Insider Monkey)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +70.98%
Oct-22-25 04:02PM	Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors (GlobeNewswire)
Oct-09-25 12:00PM	Ventyx Biosciences, Inc. (VTYX) Is Up 20.81% in One Week: What You Should Know (Zacks)
07:02AM	Loading…
Aug-27-25 07:02AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 04:05PM	Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -6.72% +19.07%
Jul-10-25 12:00PM	Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +18.33%
Jun-18-25 05:54AM	Ventyx reports positive outcomes from trial of VTX3232 for Parkinsons (Clinical Trials Arena) +7.73%
Jun-17-25 07:00AM	Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease (GlobeNewswire) -13.39%
May-28-25 08:00AM	Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 04:01PM	Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +5.98%
Apr-01-25 07:00AM	Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists (GlobeNewswire) -6.96%
Feb-27-25 04:05PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -5.23% +8.97%
Feb-18-25 08:00AM	Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025 (GlobeNewswire)
08:00AM	Loading…
Feb-05-25 08:00AM	Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-15-25 08:11AM	Ventyx Biosciences highlights its 2025 pipeline strategy (TipRanks)
Jan-14-25 08:00AM	Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio (GlobeNewswire)
Nov-12-24 11:01PM	Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress (TipRanks)
07:30AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 04:05PM	Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Oct-29-24 06:01AM	These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts (TipRanks)
Oct-15-24 08:00AM	Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 (GlobeNewswire)
Sep-23-24 01:54PM	Sanofi gains exclusivity rights to Ventyxs CNS-penetrant drug in $27m deal (Pharmaceutical Technology) +6.96%
08:00AM	Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi (GlobeNewswire)
Sep-06-24 08:00AM	Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease (GlobeNewswire)
Aug-30-24 08:00AM	Ventyx Biosciences Announces Departure of Chief Financial Officer (GlobeNewswire)
07:04AM	Novo builds heart failure case for semaglutide; Ventyx CFO departs (BioPharma Dive)
Aug-28-24 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 04:01PM	Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
05:13PM	Loading…
Jul-30-24 05:13PM	Ventyx scraps TYK2 inhibitor after Phase II Crohns defeat (Pharmaceutical Technology)
Jul-29-24 08:00AM	Ventyxs TYK2 drug suffers second setback (BioPharma Dive) -22.71%
08:00AM	Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease (GlobeNewswire)
Jun-05-24 04:01PM	Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers (GlobeNewswire) +6.77% -37.78%
May-16-24 04:05PM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire) +18.85% -5.02%
11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
08:00AM	Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer (GlobeNewswire)
May-13-24 09:02PM	VTYX ALERT: Top Law Firm Bleichmar Fonti & Auld LLP Is Investigating the Directors of Ventyx Biosciences, Inc. for Potential Breaches of Fiduciary Duty; Contact the Firm for More Details (Newsfile)
10:37AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:59PM	VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024 (InvestorPlace) -8.71%
04:01PM	Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-02-24 04:05PM	Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-30-24 12:00PM	What Makes Ventyx Biosciences (VTYX) a New Buy Stock (Zacks)
Apr-17-24 08:45AM	NASDAQ: VTYX Lawsuit Notice: Investors who lost over $100,000 with shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) should contact the Shareholders Foundation (GlobeNewswire) -7.98%
05:45AM	Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire)
Apr-15-24 01:15PM	Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Mar-27-24 06:20AM	Investors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire)
Mar-20-24 05:45AM	Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire) -5.06%
Mar-18-24 06:02PM	Robbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their Rights (Business Wire)
Mar-11-24 07:29AM	Ventyx Biosciences, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 30, 2024 deadline (GlobeNewswire) -18.95%
07:00AM	Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event (GlobeNewswire)
Mar-07-24 08:52AM	NodThera says inflammation drug has positive effect in Parkinsons (BioPharma Dive) +13.18%
08:00AM	Ventyx Biosciences Announces $100 Million Private Placement of Common Stock (GlobeNewswire)
Mar-06-24 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 08:00AM	Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024 (GlobeNewswire) +5.88%
Feb-27-24 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +28.43%
Feb-22-24 07:00AM	Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) (GlobeNewswire) +14.48%
Feb-21-24 04:09PM	Weight-Loss Drug Hype Sends Biotech Ventyxs Stock Soaring on Rivals Data (Bloomberg) +68.56%
Feb-06-24 04:05PM	Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.13%
Dec-23-23 11:01AM	Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares (GuruFocus.com)
Nov-21-23 04:05PM	Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-23 08:00AM	Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -7.17%
Nov-09-23 04:01PM	Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -5.15%
09:35AM	Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround (Zacks)
Nov-07-23 04:20PM	Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop (Investor's Business Daily) -80.62%
08:47AM	Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today? (InvestorPlace)
07:00AM	Ventyx revises TYK2 drug plans after lackluster study data (BioPharma Dive)
Nov-06-23 04:01PM	Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update (GlobeNewswire) -9.56%
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-11-23 11:37AM	Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data (Zacks) -8.87%
Oct-10-23 04:18PM	These Stocks Are Moving the Most Today: PepsiCo, Truist, Unity Software, Rivian, Electronic Arts, and More (Barrons.com) -25.93%
12:55PM	Why Shares of Ventyx Biosciences Are Dropping Tuesday (Motley Fool)
07:44AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-09-23 04:01PM	Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis (GlobeNewswire)
Oct-07-23 05:00AM	CEO Raju Mohan Sells 30,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com)
Oct-04-23 11:01PM	Insider Sell: Christopher Krueger Sells 15,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com) -5.98%
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-08-23 05:07PM	Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc (GuruFocus.com)
Aug-30-23 04:05PM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-15-23 07:23AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 04:01PM	Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +6.38%
Aug-03-23 04:05PM	Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Aug-02-23 04:06PM	Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-12-23 07:22AM	Daily Vickers Top Buyers & Sellers for 07/12/2023 (Argus Research) -5.95%
Jul-03-23 02:09PM	Why Shares of Ventyx Biosciences Rose Monday (Motley Fool) +22.87%
Jun-14-23 07:00AM	Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Jun-07-23 07:00AM	Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis (GlobeNewswire)
May-31-23 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-12-23 08:57AM	Q1 2023 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.11%
May-11-23 04:01PM	Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-04-23 04:05PM	Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Mar-27-23 07:12AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 11:13AM	Q4 2022 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.23%
08:00AM	Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-23-23 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Mar-15-23 04:05PM	Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023 (GlobeNewswire)
Mar-13-23 09:02AM	Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-11-23 01:21PM	Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure (GlobeNewswire)
Feb-28-23 08:00AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-23 08:50AM	Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why (Zacks)

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nuss John	CHIEF SCIENTIFIC OFFICER	Apr 02 '25	Sale	1.07	1,887	2,019	467,226	Apr 03 04:21 PM
Mohan Raju	CEO AND PRESIDENT	Mar 28 '25	Option Exercise	0.00	11,844	0	2,303,540	Apr 01 04:36 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Mar 28 '25	Option Exercise	0.00	4,531	0	469,113	Apr 01 04:35 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 27 '24	Sale	2.36	21,119	49,841	464,582	Dec 30 05:33 PM
Nuss John	Officer	Dec 27 '24	Proposed Sale	2.36	21,119	49,842		Dec 27 04:46 PM
Gujrathi Sheila	Director	Dec 23 '24	Buy	2.31	130,000	300,573	130,000	Dec 26 08:05 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 17 '24	Option Exercise	0.00	34,930	0	498,862	Dec 19 06:50 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 19 '24	Sale	2.26	13,161	29,682	485,701	Dec 19 06:50 PM
Mohan Raju	CEO AND PRESIDENT	Dec 17 '24	Option Exercise	0.00	116,668	0	2,291,696	Dec 19 06:49 PM
Nuss John	Officer	Dec 19 '24	Proposed Sale	2.26	13,161	29,682		Dec 19 06:48 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 10 '24	Option Exercise	0.20	198,934	39,787	463,932	Dec 11 05:21 PM
Mohan Raju	CEO AND PRESIDENT	Nov 25 '24	Buy	2.01	261,752	524,944	2,175,028	Nov 25 09:07 PM
Mohan Raju	CEO AND PRESIDENT	Nov 22 '24	Buy	1.83	238,248	434,946	1,913,276	Nov 25 09:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTYX

Ventyx Biosciences Inc

Upgrade your FINVIZ experience